The diversity of the immune response to the A2 domain of human factor VIII.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Blood

• Publication date

  2013-04-04

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1182/blood-2012-09-456582PMID 23349389PMCID PMC3617638
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple Antigenic Sites Are Involved in Blocking the Interaction of GII.4 Norovirus Capsid with ABH Histo-Blood Group Antigens

  2012cited by this paper
• West Nile virus: characterization and diagnostic applications of monoclonal antibodies

  2012cited by this paper
• Dynamic antibody-binding properties in the pathogenesis of HIT.

  2012cited by this paper
• A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

  2011cited by this paper
• The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes

  2011cited by this paper
• Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.

  2011cited by this paper
• Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

  2010cited by this paper
• Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.

  2008cited by this paper
• Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.

  2008cited by this paper
• The tertiary structure and domain organization of coagulation factor VIII.

  2008cited by this paper
• Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.

  2007cited by this paper
• The humoral response to human factor VIII in hemophilia A mice

  2007cited by this paper
• Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII

  2006cited by this paper
• A1 Subunit-mediated Regulation of Thrombin-activated Factor VIII A2 Subunit Dissociation*

  2006cited by this paper
• The safety and efficacy of B‐domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update

  2005cited by this paper
• The safety and efficacy of B‐domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A

  2003cited by this paper
• Low detection rate of antibodies to non‐functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay

  2003cited by this paper
• Human Inhibitor Antibodies Specific for the Factor VIII A2 Domain Disrupt the Interaction between the Subunit and Factor IXa*

  1999cited by this paper
• Factor VIII Inhibitors

  1997cited by this paper
• The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.

  1997cited by this paper
• The X-ray structure of human serum ceruloplasmin at 3.1 Å: nature of the copper centres

  1996cited by this paper
• Kinetics of factor VIII light-chain cleavage by thrombin and factor Xa. A regulatory role of the factor VIII heavy-chain region Lys713-Arg740.

  1996cited by this paper
• Cleavage of Factor VIII Light Chain Is Required for Maximal Generation of Factor VIIIa Activity (*)

  1995cited by this paper
• Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII (*)

  1995cited by this paper
• Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site.

  1994cited by this paper
• Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

  1994cited by this paper
• Elimination of a major inhibitor epitope in factor VIII.

  1994cited by this paper
• A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.

  1994cited by this paper
• Relative topography of biologically active domains of human vitronectin. Evidence from monoclonal antibody epitope and denaturation studies.

  1994cited by this paper
• Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

  1993cited by this paper
• Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).

  1992cited by this paper
• A Soluble Recombinant Factor VIII Fragment Containing the A2 Domain Binds to Some Human Anti-Factor VIII Antibodies that Are not Detected by Immunoblotting

  1992cited by this paper
• Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity.

  1991cited by this paper
• Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit.

  1991cited by this paper
• von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain.

  1990cited by this paper
• Characterization of a thrombin cleavage site mutation (Arg 1689 to Cys) in the factor VIII gene of two unrelated patients with cross-reacting material-positive hemophilia A.

  1990cited by this paper
• pH-dependent denaturation of thrombin-activated porcine factor VIII.

  1990cited by this paper
• Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372----histidine).

  1989cited by this paper
• Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.

  1989cited by this paper
• Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments.

  1989cited by this paper
• Association of the factor VIII light chain with von Willebrand factor.

  1988cited by this paper
• Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII).

  1988cited by this paper
• Immunochemical characterization of factor VIII inhibitors.

  1984cited by this paper
• Human factor VIII procoagulant activity and phospholipid interaction.

  1981cited by this paper
• Interaction Of Factor VIII/Von Willebrand Factor With Phospholipid Vesicles

  1981cited by this paper
• Clonal analysis of B- and T-cell responses to Ia antigens

  1981cited by this paper
• Letter: A more uniform measurement of factor VIII inhibitors.

  1975cited by this paper

• Regulation of immune responses to therapeutic factor VIII by transplacental delivery of Fc-fused immunodominant factor VIII domains or peptides

  2025cites this paper
• Standardization of FVIII neutralization for functional Emicizumab Quantification in Presence of Various FVIII Sources.

  2025cites this paper
• Persistent Splenic-Derived IgM Preferentially Recognize Factor VIIIA2 and C2 Domain Epitopes but Do Not Alter Antibody Production.

  2024cites this paper
• Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies.

  2024cites this paper
• Discovery and Characterization of Panaxatriol as a Novel Thrombin Inhibitor from Panax notoginseng Using a Combination of Computational and Experimental Approaches

  2024cites this paper
• Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner

  2023cites this paper
• Structural and Thermodynamic Studies of Antibody Binding to Blood Coagulation Factor VIII

  2023influential citation
• Structural insights into blood coagulation factor VIII: Procoagulant complexes, membrane binding, and antibody inhibition

  2022cites this paper
• Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay

  2022cites this paper
• Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China

  2022cites this paper
• Structure of Blood Coagulation Factor VIII in Complex with Anti-C2 Domain Inhibitory Antibody

  2021cites this paper
• Removal of single‐site N‐linked glycans on factor VIII alters binding of domain‐specific monoclonal antibodies

  2021cites this paper
• Novel Coagulation Factor VIII Gene Therapy in a Mouse Model of Hemophilia A by Lipid-Coated Fe3O4 Nanoparticles

  2021cites this paper
• Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor

  2021cites this paper
• Plasma-derived factors VIIa and X mixtures (Byclot®) significantly improve impairment of coagulant potential ex vivo in plasmas from acquired hemophilia A patients

  2020cites this paper
• Clinical Care of a Child with Hemophilia A and Inhibitors

  2020cites this paper
• Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII

  2020cites this paper
• Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor

  2020influential citation
• The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain

  2020cites this paper
• Plant cell-made protein antigens for induction of Oral tolerance

  2019cites this paper
• Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.

  2019cites this paper
• Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity

  2018cites this paper
• Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A

  2018cites this paper
• Structural Characterization of a Human/Porcine Chimeric FVIII Construct and an Improved Human Factor VIII Model and Progress Towards Determination of the FVIII C1 Domain In Complex With Inhibitory Antibodies

  2018cites this paper
• Screening and Characterization Strategies for Nanobodies Targeting Membrane Proteins.

  2017cites this paper
• Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

  2016cites this paper
• Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction

  2016influential citation
• Detection and Prediction of Factor VIII Antibody Formation in Congenital and Acquired Haemophilia A

  2016cites this paper
• Engineering less immunogenic and antigenic FVIII proteins.

  2016cites this paper
• Neutralisation of factor VIII inhibitors by anti-idiotypes isolated from phage-displayed libraries

  2016cites this paper
• High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

  2016cites this paper
• A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII.

  2016influential citation
• Innovating immune tolerance induction for haemophilia

  2016cites this paper
• Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene

  2016cites this paper
• Structure of the Human Factor VIII C2 Domain in Complex with the 3E6 Inhibitory Antibody

  2015cites this paper
• Lentiviral vectors for gene therapy of Gaucher disease

  2015cites this paper
• Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors

  2015cites this paper
• Computer‐predicted peptides that mimic discontinuous epitopes on the A2 domain of factor VIII

  2015cites this paper
• Structural and functional aspects of factor viii in the initiation of the anti-factor viii immune response

  2014cites this paper
• Epitope mapping via selection of anti-FVIII antibody-specific phagepresented peptide ligands that mimic the antibody binding sites

  2014cites this paper
• The 1.7 Angstrom X-Ray Crystal Structure of the Porcine Factor VIII C2 Domain and Binding Analysis to Anti-Human C2 Domain Antibodies and Phospholipid Surfaces

  2014cites this paper
• Suppression of Inhibitor Formation against Factor VIII in Hemophilia A Mice by Oral Delivery of Antigens Bioencapsulated in Plant Cells

  2014cites this paper
• Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells.

  2014cites this paper
• High-Throughput Epitope Binning Assays on Label-Free Array-Based Biosensors Can Yield Exquisite Epitope Discrimination That Facilitates the Selection of Monoclonal Antibodies with Functional Activity

  2014cites this paper
• Selektion und Charakterisierung FVIII-spezifischer einzelkettiger Antikörperfragmente

  2013cites this paper
• Selection and characterisation of FVIII-specific single chain variable fragments

  2013cites this paper